AU2017229364A1 - Compositions and methods for treating rheumatoid arthritis - Google Patents

Compositions and methods for treating rheumatoid arthritis Download PDF

Info

Publication number
AU2017229364A1
AU2017229364A1 AU2017229364A AU2017229364A AU2017229364A1 AU 2017229364 A1 AU2017229364 A1 AU 2017229364A1 AU 2017229364 A AU2017229364 A AU 2017229364A AU 2017229364 A AU2017229364 A AU 2017229364A AU 2017229364 A1 AU2017229364 A1 AU 2017229364A1
Authority
AU
Australia
Prior art keywords
antibody
ser
val
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017229364A
Other languages
English (en)
Inventor
Deborah Bauer
Alexander BODDY
Neil Graham
Yong Lin
Janie PARRINO
Rahul Patel
Janet VAN ADELSBERG
Hubert VAN HOOGSTRATEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16305253.3A external-priority patent/EP3216461A1/en
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of AU2017229364A1 publication Critical patent/AU2017229364A1/en
Priority to AU2024203011A priority Critical patent/AU2024203011A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017229364A 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis Abandoned AU2017229364A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203011A AU2024203011A1 (en) 2016-03-07 2024-05-07 Compositions and methods for treating rheumatoid arthritis

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16305253.3A EP3216461A1 (en) 2016-03-07 2016-03-07 Compositions and methods for treating rheumatoid arthritis
EP16305253.3 2016-03-07
EP16170664.3 2016-05-20
EP16170664 2016-05-20
EP16306111.2 2016-09-05
EP16306111 2016-09-05
PCT/US2017/021149 WO2017155990A1 (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203011A Division AU2024203011A1 (en) 2016-03-07 2024-05-07 Compositions and methods for treating rheumatoid arthritis

Publications (1)

Publication Number Publication Date
AU2017229364A1 true AU2017229364A1 (en) 2018-10-25

Family

ID=58387910

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017229364A Abandoned AU2017229364A1 (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis
AU2024203011A Pending AU2024203011A1 (en) 2016-03-07 2024-05-07 Compositions and methods for treating rheumatoid arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203011A Pending AU2024203011A1 (en) 2016-03-07 2024-05-07 Compositions and methods for treating rheumatoid arthritis

Country Status (18)

Country Link
US (1) US20190100585A1 (enExample)
EP (1) EP3426295A1 (enExample)
JP (2) JP7166925B2 (enExample)
KR (2) KR20180114955A (enExample)
CN (1) CN109069642A (enExample)
AU (2) AU2017229364A1 (enExample)
BR (1) BR112018067851A2 (enExample)
CA (1) CA3016880A1 (enExample)
CL (1) CL2018002559A1 (enExample)
CR (1) CR20180465A (enExample)
EA (1) EA201892005A1 (enExample)
IL (2) IL308539A (enExample)
MX (2) MX2018010815A (enExample)
PH (1) PH12018501894A1 (enExample)
SG (2) SG11201807614SA (enExample)
TN (1) TN2018000312A1 (enExample)
TW (3) TW202419103A (enExample)
WO (1) WO2017155990A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2019105450A1 (zh) * 2017-11-30 2019-06-06 百奥泰生物制药股份有限公司 一种治疗il-6相关疾病的人源化抗体的液体制剂
KR20210049871A (ko) * 2018-08-29 2021-05-06 리제너론 파아마슈티컬스, 인크. 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물
TWI860325B (zh) * 2019-01-31 2024-11-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
BR112021021077A2 (pt) * 2019-04-24 2021-12-14 E Zilberstein Moshe Métodos de diagnóstico e tratamento de artrite reumatoide
MX2021014892A (es) * 2019-06-04 2022-06-27 Sanofi Biotechnology Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide.
WO2023020563A1 (en) * 2021-08-18 2023-02-23 Bio-Thera Solutions, Ltd. Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2385745C (en) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
CA2930615C (en) * 2013-11-22 2023-04-04 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same

Also Published As

Publication number Publication date
JP7745529B2 (ja) 2025-09-29
CL2018002559A1 (es) 2019-03-01
TN2018000312A1 (en) 2020-01-16
TW202419103A (zh) 2024-05-16
IL261515B2 (en) 2024-04-01
KR20230093522A (ko) 2023-06-27
WO2017155990A1 (en) 2017-09-14
BR112018067851A2 (pt) 2019-02-05
JP7166925B2 (ja) 2022-11-08
CR20180465A (es) 2019-03-04
AU2024203011A1 (en) 2024-07-11
EP3426295A1 (en) 2019-01-16
PH12018501894A1 (en) 2019-05-15
KR20180114955A (ko) 2018-10-19
JP2019507775A (ja) 2019-03-22
CA3016880A1 (en) 2017-09-14
NZ746988A (en) 2023-10-27
IL261515A (en) 2018-10-31
JP2023011711A (ja) 2023-01-24
SG10202012182YA (en) 2021-01-28
IL261515B1 (en) 2023-12-01
TW201808993A (zh) 2018-03-16
TW202239767A (zh) 2022-10-16
IL308539A (en) 2024-01-01
SG11201807614SA (en) 2018-10-30
TWI819435B (zh) 2023-10-21
TWI747885B (zh) 2021-12-01
EA201892005A1 (ru) 2019-02-28
MX2023014841A (es) 2024-01-15
US20190100585A1 (en) 2019-04-04
MX2018010815A (es) 2019-01-10
CN109069642A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
JP7745529B2 (ja) 関節リウマチを処置するための組成物及び方法
US20230127528A1 (en) Compositions and methods for treating juvenile idiopathic arthritis
US20220041708A1 (en) Pharmaceutical Composition for Safe and Effective Treatment of Knee and/or Hip Pain
US20230399410A1 (en) Compositions and methods for treating polymyalgia rheumatica by administering an il-6r antagonist
US20230174657A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
AU2017366870B2 (en) A pharmaceutical composition for averting opioid addiction
US20230192871A1 (en) Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis
NZ746988B2 (en) Compositions and methods for treating rheumatoid arthritis
RU2822089C2 (ru) Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита
EP4157872A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
WO2025166169A1 (en) Compositions, doses, and methods for treatment of c1s mediated diseases and disorders

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted